Company / Total Assets
Astria Therapeutics, Inc. Total Assets History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$342.4M
FY2024
5-year range
$47.5M / $342.4M
FY2020-FY2024
Trend
+34.4%
vs FY2023
Sector context
#174 of 214
Health Care
What the data says
Astria Therapeutics, Inc.'s total assets of $342M is lower than 81% of companies in the Health Care sector (FY2024). Total Assets has increased for 7 consecutive years, from $18M in FY2017 to $342M in FY2024.
Based on SEC 10-K filings.
$342M in FY2024 with a 5-year CAGR of +52.3%.
Improved from $231M to $342M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +39.0%
- 5-Year CAGR
- +52.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 214This company $342.4M Sector average $7.5B
▼
-95.4% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s total assets has grown for 7 consecutive years.
- 5-year CAGR of +52.3%, indicating consistent growth.
- In FY2024, total assets increased 34.4% year-over-year.
- Ranks #174 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $342.4M | +34.4% |
| FY2023 | $254.7M | +10.4% |
| FY2022 | $230.6M | +80.9% |
| FY2021 | $127.5M | +168.7% |
| FY2020 | $47.5M | +13.6% |
| FY2019 | $41.8M | +6.7% |
| FY2018 | $39.2M | +118.9% |
| FY2017 | $17.9M | -55.5% |
| FY2016 | $40.2M | -37.3% |
| FY2015 | $64.2M | +302.0% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026